Who benefits most from GLP-1 receptor agonists?

Who gets the biggest benefits from GLP-1 agonists?

The clearest, strongest evidence points to three groups: people with type 2 diabetes who also have obesity or heart disease, people with obesity alone, and—more recently—people with Parkinson's disease. In a massive VA study of over 215,000 people with diabetes, those taking a GLP-1 agonist had lower risks of major cardiovascular events, dementia, and even substance use disorders compared to people on other diabetes drugs [8]. That study is the largest and most comprehensive here, mapping 175 health outcomes. For weight loss alone, a phase 2 trial found that 46–75% of people with obesity (without diabetes) lost at least 10% of their body weight over 36 weeks on the oral GLP-1 drug orforglipron, versus 9% on placebo [2]. And for Parkinson's disease, a meta-analysis of randomized trials showed that GLP-1 agonists improved motor scores by about 2.5 points and cognitive scores by 1.3 points compared to placebo [1].

But not everyone responds equally. A genome-wide study of over 4,500 people with type 2 diabetes found that people with a specific variant in the ARRB1 gene—more common in Hispanic and American Indian populations—had a 0.25% greater drop in HbA1c (a key blood sugar measure) than those without it. Combining two gene variants, the top 4% of responders had a 30% greater HbA1c reduction than the bottom 9% [3]. So genetic testing could one day identify who will benefit most, but it's not yet routine.

The gap between best-case and typical results: what the average person should expect

The headline numbers from trials—like 15% weight loss or dramatic heart protection—come from carefully selected patients who stick with the drug. Real-world results are often more modest. For example, one real-world study of 550 people with type 2 diabetes found that those who stopped their GLP-1 agonist had a 3.4 times higher risk of a major cardiovascular event compared to those who stayed on it, regardless of weight or blood sugar changes [4]. That means the benefit depends heavily on staying on the drug long-term, which can be hard because of side effects. In the orforglipron weight-loss trial, 10–17% of people stopped the drug due to gastrointestinal side effects like nausea and vomiting [2].

Also, GLP-1 agonists are not risk-free. The large VA study found an increased risk of gastrointestinal disorders, pancreatitis, and kidney stones [8]. And a French database study of over 2,500 thyroid cancer cases found that using a GLP-1 agonist for 1–3 years was linked to a 58% higher risk of all thyroid cancers and a 78% higher risk of medullary thyroid cancer [9]. So while the benefits can be substantial for many, the typical person should expect a trade-off: meaningful weight loss and blood sugar improvement, but with a real chance of GI side effects and a small, uncertain risk of thyroid issues.

Surprising benefits beyond diabetes and weight loss

GLP-1 agonists appear to help in conditions you might not expect. For people with Parkinson's disease, a meta-analysis of randomized trials found that these drugs improved motor function (by about 2.5 points on a standard scale) and cognitive scores (by 1.3 points) compared to placebo [1]. That suggests a potential disease-modifying effect, though the authors note more research is needed. For people with type 1 diabetes—who are not the typical target for these drugs—a small study of 49 patients found that after one year of GLP-1 use, weight dropped from 97.6 kg to 90.0 kg and HbA1c fell from 8.2% to 7.6%, while insulin doses decreased [5]. That's an off-label use, but it shows promise for a group that often struggles with insulin-related weight gain.

Even more unexpected: a large database study of over 2,400 people who had multilevel cervical spine fusion surgery found that those taking a GLP-1 agonist had significantly lower rates of failed fusion (pseudarthrosis) at 6 months, 1 year, and 2 years after surgery—about 13% vs. 19% for anterior fusion, and 17% vs. 24% for posterior fusion [6][7]. The authors suggest this may be because GLP-1 agonists boost bone-forming cells and suppress bone-breakdown cells. And a review article even raises the possibility that these drugs could slow aging itself, by improving mitochondrial function and reducing inflammation [10]. While that's speculative, the breadth of benefits—from brain to bone to heart—is striking.

About These Sources

This answer is built on 10 peer-reviewed studies — published from 2022 to 2025, 6 from 2024 or later, 6 in Q1 journals, collectively cited 943 times — selected as the most relevant from 14 studies that passed quality screening, drawn from 64 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions